Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qin Huang Fang (芩黄方) is a traditional Chinese medicine (TCM) herbal formula under clinical investigation as an adjunctive maintenance therapy for elderly patients with diffuse large B-cell lymphoma (DLBCL) who have achieved complete or partial remission after first-line chemotherapy. The formula is being studied for its potential to improve 2-year disease-free survival rates, enhance quality of life, and modulate immune cell subtypes and metabolic profiles in this patient population. Mechanistically, research projects have focused on elucidating the pharmacological basis and multi-target actions of Qin Huang Fang in lymphoma treatment, though specific molecular targets are not fully characterized. It is administered orally as a decoction or granule formulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qin huang fang.